Kezar Life Sciences logo
Kezar Life Sciences
KZR | NASDAQ
Chart Builder DCF Calculator
$7.29
$0.00 (0.00%)
At close: May 8, 2026, 4:00 PM ET

Kezar Life Sciences Company Profile

Company profile explained

Company Profile

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.

Key Executives

Name Position
Christopher J. Kirk Co-Founder, Chief Executive Officer & Director
Marc L. Belsky Chief Financial Officer & Secretary
Jack Taunton Co-Founder
John Franklin Fowler Co-Founder & Director
Mark Schiller Chief Operations Officer
Pichi Chiang Senior Vice President & Controller

Latest SEC Filings

Date Type Title
May 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 21, 2026 15-12G Filing
May 14, 2026 EFFECT Filing
May 13, 2026 SC 13D/A [Amend] Filing
May 12, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 12, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 11, 2026 4 Filing
May 11, 2026 4 Filing
May 11, 2026 4 Filing
May 11, 2026 4 Filing
View All SEC Filings ➞
Kezar Life Sciences
Kezar Life Sciences logo
Country United States
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Christopher J. Kirk

Contact Details

4000 Shoreline Court South San Francisco, California 94080 United States

Stock Details

Ticker Symbol KZR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645666
CUSIP Number 49372L209
ISIN Number US49372L2097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.